Pharma major Zydus Cadila on Thursday entered into an agreement with Mayne Pharma of Australia to set up a 50:50 joint venture company
Ahmedabad-based Zydus Cadila has made a foray into the US generic formulation segment by setting up a subsidiary Zydus Pharmaceuticals USA, Inc.
ZyCoV-D is a three-dose vaccine administered intradermally.
Cadila Healthcare Ltd has announced that Zydus Cadila has received its very first approval from USFDA to market Atenolol, an anti-hypertensive drug, in the US market.
Drug firm Zydus Cadila on Thursday said it has applied for emergency use authorisation (EUA) with the Indian drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture 10-12 crore doses annually.
Zydus Cadila Healthcare Ltd on Tuesday said it has received approval from the French regulatory agency, AFSSAPS, to market Sertraline capsules 25 mg and 50 mg, in the French market.
The seven states are Bihar, Jharkhand, Maharashtra, Punjab, Tamil Nadu, Uttar Pradesh and West Bengal.
Zydus Cadila Healthcare on Monday said its net profit during 2003-04 increased by 86.68 per cent to Rs 143 crore (Rs 1,430 million) as against Rs 76.6 crore (Rs 766 million) in the previous year.
Zydus Cadila has agreed to bring down the price of its COVID-19 vaccine to Rs 265 a dose following persistent negotiations by the government but a final deal is yet to be reached, sources said on Sunday.
Ahmedabad-based Zydus Cadila group has filed 12 Abbreviated New Drug Applications in fiscal 2003-04 even as the company has set a target to file 16-18 ANDAs in the current financial year.
So far, no other vaccine has been approved globally for children below 12 years. Sohini Das reports.
With talks underway between the central government and Zydus Cadila over the pricing of the COVID-19 vaccine ZyCov-D, the pharma company is learnt to have proposed a price of Rs 1,900 for its three-dose jab that can be given to those above 12 years of age.
This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das
The company said the drug will be made available across India through the group's strong distribution chain reaching out to government and private hospitals treating COVID-19 patients.
Zydus Pharmaceuticals Inc, the US arm of Zydus Cadila has entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare to market generic products in the US.
This is the world's first DNA-based vaccine against the coronavirus, and this three-dose vaccine when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance
Ahmedabad-based Zydus Cadila, India's fourth largest pharma company with a turnover of Rs 2,300 crore, has acquired 100 per cent stake in Laboratorios Combix of Spain, marking its entry into Europe's fifth largest pharmaceutical market. The company bought the Spanish firm for an undisclosed amount.
This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark.
Can Interferon alfa-2b treat COVID-19 effectively?
Ahmedabad-based Zydus Cadila, Bharat Biotech's intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.
Union Health Minister Mansukh Mandaviya on Tuesday told Bharatiya Janata Party MPs that Covid vaccination for children is likely to start soon, sources said.
Acquisition of popular brands such as Complan, Glucon D, Nycil and Sampriti Ghee from Heinz India would be a part of the deal, Cadila Healthcare said in a filing to BSE.
As the Omicron variant of Sars-CoV-2 takes centrestage, vaccine makers in India are of the view that scaling up the existing vaccines to make them more effective is possible.
The trial is being conducted in three phases by segregating children into categories according to their age. The first trial was started in the age group of 12 to 18 years followed by the age group of 6 to 12. Trials for children between the ages of and 2-6 years are currently undergoing trials.
Modi on Saturday will embark on a three-city tour to take stock of the COVID-19 vaccine development work.
Ahmedabad was the first stop in the PM's three city tour today, to personally review the vaccine development and manufacturing process in the country.
Zydus Cadila COVID-19 vaccine for children above 12 years is expected to be available by August as its trials are likely to be completed by July-end, said Dr N K Arora, Chairman, National Technical Advisory Group on Immunisation (NTAGI).
While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
The Central Drugs Standard Control Organisation said while the rights, safety, and well-being of trial subjects were of paramount importance, protocol amendment, deviation or modification might be necessary in some cases owing to unavoidable circumstances.
Pharma majors are collaborating with foreign companies to develop newer drugs.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
Generic drug sales in the US, that power the business of such leading Indian drug manufacturers as Ranbaxy, Dr Reddy's, Sun Pharma, Lupin and Zydus Cadila, will face competition soon, as big US wholesalers decide to outsource their requirements from upcoming Indian manufacturers.
While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances